Neurable Raises $35 Million In Series A Funding Round

Neurable recently secured $35 million in a Series A funding round, bringing its total funding to $65 million. The round was led by Spectrum Moonshot Fund, with participation from existing investors such as Pace Ventures.

Neurable is a Boston-based neurotechnology company founded in 2011 as a spin-out from the University of Michigan, specializing in noninvasive brain-computer interfaces (BCIs) that translate brain signals into actionable insights. Led by CEO and Co-Founder Dr. Ramses Alcaide, the company aims to make brain data as accessible as fitness metrics, integrating BCI into everyday devices like the MW75 Neuro LT headphones, which use EEG sensors to monitor focus, fatigue, and cognitive recovery in real time.

Recent Series A round positions Neurable to scale its Neurable AI platform, which enhances signal to noise ratios in brain data for high performance applications. Prior to this, Neurable had raised over $30 million, including a $13 million round in May 2024 from investors like Ultratech Capital Partners, TRAC, Pace Ventures, and Metaplanet. The new capital will fuel expansion into gaming and broader cognitive health ecosystems.

Research suggests this funding could propel Neurable’s growth in a BCI market projected to reach $52 billion by 2034, emphasizing noninvasive solutions for consumer use. It may enhance partnerships, such as with iMotions for research tools and Master & Dynamic for audio tech, while addressing ethical concerns around brain data privacy. The involvement of family office funds like Spectrum Moonshot indicates confidence in long-term potential, though competition from invasive players like Neuralink adds complexity.

Neurable, a pioneering neurotechnology firm headquartered in Boston, Massachusetts, has recently closed a significant $35 million Series A funding round, marking a pivotal moment in its journey to democratize brain-computer interface (BCI) technology for everyday applications. Founded in 2011 as a spin-out from the University of Michigan’s Innovation Partnerships accelerator, Neurable specializes in developing AI powered tools that translate brain signals into practical insights, enabling high performance BCIs integrated into consumer devices. Under the leadership of CEO and Co-Founder Dr. Ramses Alcaide, whose personal experiences, including immigrating from Mexico and witnessing a family member’s limitations due to injury, drove the company’s mission, Neurable seeks to bridge the gap between human cognition and technology, making brain data as intuitive and accessible as checking step counts or heart rates on a smartwatch.

The company’s core innovation lies in its patented Neurable AI platform, which processes brain signals with exceptional accuracy, enhancing signal to noise ratios to deliver real time metrics on focus, mental fatigue, and cognitive recovery. This technology powers products like the MW75 Neuro LT headphones, developed in partnership with Master & Dynamic, which embed fabric based electroencephalography (EEG) sensors into wireless audio devices for seamless, noninvasive monitoring. Validated through independent evaluations and peer reviewed studies, these capabilities allow users to track mental states with high fidelity, preventing burnout and optimizing performance in daily routines. Beyond consumer wellness, Neurable’s platform extends to research and emerging sectors, with recent collaborations including iMotions, a leading human behavior research platform, for integrating neural data into software suites, and MeSpace for studying adaptive workstations’ impact on cognitive performance.

This latest funding round, announced in December 2025, was led by Spectrum Moonshot Fund, a family office investment firm. Known for actively seeking investments in innovative technologies, the fund has an average round investment of around $9.22 million and focuses on building powerful platforms in emerging spaces. Participation also came from existing investors, notably Pace Ventures, a firm that views Neurable as a leader in translating scientific breakthroughs into accessible consumer products for healthier lives. The $35 million infusion brings Neurable’s total funding to $65 million, underscoring investor confidence in its trajectory amid a burgeoning BCI market expected to exceed $52 billion globally by 2034.

Recommended: Cyphlens Raises $3.8 Million In Seed Funding Round

The capital is earmarked to accelerate the commercialization of Neurable AI, expanding its integration into broader ecosystems for cognitive health and human performance. A key focus area is gaming and e-sports, where marginal improvements in concentration, reaction times, and cognitive endurance can yield competitive edges; Neurable plans to embed brain insights directly into gaming workflows and devices, potentially revolutionizing player performance and game design. Additionally, the funding will bolster research applications and new BCI enabled product categories, positioning brain data as a foundational element in work, play, and well being. CEO Alcaide emphasized the goal of making brain understanding a daily utility, while Investment Manager Mauro Guebeli of Spectrum Value Management praised the team’s ability to deliver high quality BCI in elegant consumer products. Pace Ventures’ Managing Partner Marius Swart highlighted the potential for more conscious lives, and Co-Founder Adam Molnar noted gaming’s intuitive fit for the technology.

Neurable’s funding history reflects steady progression from early stage investments to this milestone round. The company has attracted 23 investors overall, including entities like National Science Foundation, Global Brain Corporation, FundersClub, Hartmann Capital, and Innospark Ventures. Key prior rounds include a $2 million seed in December 2016, led by Boston Syndicates, which supported initial development of brain controlled software for AR and VR. Subsequent investments encompassed a $1.03 million round in March 2019, undisclosed amounts in September 2021 and April 2023 (from Global Brain Corporation and Hartmann Capital), and a $13 million venture round in May 2024 from Ultratech Capital Partners, TRAC, Pace Ventures, and Metaplanet, which advanced platform scaling and licensing across industries. That 2024 round brought totals to over $30 million, setting the stage for the current expansion. Note that round classifications vary across sources, with some labeling earlier investments as Series A or B, but official communications designate the December 2025 raise as Series A.

Funding Rounds History Table

This progression illustrates Neurable’s evolution from academic roots to a consumer focused innovator, with cumulative funding now enabling aggressive market entry. The investment landscape reflects broader trends in neurotech, where noninvasive BCIs are gaining traction over invasive alternatives, driven by consumer demand for ethical, user friendly tools. However, as brain data becomes commoditized, stakeholders must navigate privacy concerns, with Neurable emphasizing intuitive and ethical access. Looking ahead, this round could catalyze further partnerships and product iterations, potentially positioning Neurable as a frontrunner in transforming cognitive health into a mainstream category, akin to the rise of wearables in physical fitness. Social media reactions, including announcements from the CEO and industry observers, indicate excitement about the technology’s real world implications, though some express caution regarding data security in an era of advancing AI.

Please email us your feedback and news tips at hello(at)www.dailycompanynews.com